- Home
- ORIC vs ARVN Comparison
ORIC vs ARVN Comparison
Compare ORIC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | ARVN |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.0M | 781.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ORIC | ARVN |
|---|---|---|
| Price | $8.56 | $12.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 23 |
| Target Price | ★ $19.73 | $18.14 |
| AVG Volume (30 Days) | ★ 1.4M | 846.9K |
| Earning Date | 02-17-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $312,300,000.00 |
| Revenue This Year | N/A | $11.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $3.90 | $5.90 |
| 52 Week High | $14.93 | $20.63 |
Technical Indicators
Market Signals| Indicator | ORIC | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 53.63 |
| Support Level | $7.84 | $11.01 |
| Resistance Level | $8.92 | $12.74 |
| Average True Range (ATR) | 0.38 | 0.52 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 67.28 | 68.01 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.